Sponsor or institution

Clinical trials and research at Jiangsu Alphamab Biopharmaceuticals Co., Ltd

• 7Clinical trials
• 1Country

Newest trials

All recruiting trials (7)

• First-in-human test of JSKN021 in advanced solid tumors

  This phase 1 study will test the safety and basic activity of JSKN021 in adults with advanced solid tumors who have exhausted standard treatments.

  Recruiting at 10 sites Phase 1 Jiangsu Alphamab Biopharmaceuticals Co., Ltd · Fuzhou, Fujian and 9 other locations · NCT07617727

• JSKN016 versus physician's choice for advanced triple-negative breast cancer after prior treatments

  This trial will test whether JSKN016 works better than a physician's choice chemotherapy for adults with unresectable locally advanced, recurrent, or metastatic triple-negative breast cancer who have already had at least two prior systemic chemotherapies.

  Recruiting Phase 3 Jiangsu Alphamab Biopharmaceuticals Co., Ltd · Guangzhou, Guangdong · NCT07533123

• JSKN022 for advanced malignant solid tumors

  This will test whether JSKN022 is safe and tolerable for adults with advanced unresectable or metastatic epithelial solid tumors who have exhausted or cannot receive standard treatments.

  Recruiting Phase 1 Jiangsu Alphamab Biopharmaceuticals Co., Ltd · Guangzhou, Guangdong · NCT07292402

• JSKN016 combined with chemotherapy or immunotherapy for inoperable or metastatic HER2-negative breast cancer

  This study will test whether adding JSKN016 to chemotherapy or immunotherapy helps people whose HER2-negative breast cancer cannot be removed by surgery or has spread to other parts of the body.

  Recruiting Phase 1/2 Jiangsu Alphamab Biopharmaceuticals Co., Ltd · Shanghai · NCT06942234

• JSKN016 combination therapy for advanced non-small cell lung cancer

  The study will try combining JSKN016 with chemotherapy or targeted antibodies to see if it helps adults whose non-small cell lung cancer is locally advanced or has spread.

  Recruiting Phase 1 Jiangsu Alphamab Biopharmaceuticals Co., Ltd · Guangzhou, Guangdong · NCT06868732

• Evaluating JSKN016 in patients with advanced malignant solid tumors

  This study is testing a new drug called JSKN016 to see if it is safe and what the right dose is for people with advanced solid tumors that have spread.

  Recruiting at 2 sites Phase 1 Jiangsu Alphamab Biopharmaceuticals Co., Ltd · Fuzhou, Fujian and 1 other locations · NCT06592417

• JSKN003 versus physician's choice chemotherapy for HER2-low advanced breast cancer

  This trial will test whether the experimental drug JSKN003 works better than standard single‑agent chemotherapies for adults with HER2‑low, unresectable or metastatic breast cancer who have had one or two prior chemotherapy regimens.

  Recruiting at 42 sites Phase 3 Jiangsu Alphamab Biopharmaceuticals Co., Ltd · Guangzhou, Guangdong and 86 other locations · NCT06079983

Quick answers

How many clinical trials run by Jiangsu Alphamab Biopharmaceuticals Co., Ltd are recruiting right now?

7, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

All of them have sites in China. Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 1: 4, Phase 3: 2, Phase 1/2: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →